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Historically, quantitation of virus-specific CD8+ T cells
has been accomplished by limiting dilution analysis of
cytotoxic precursor cells. Recent studies have shown
that this technique greatly underestimates the actual
number of antigen-specific cells and have provided new
insight into anti-viral immune responses.
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It has long been recognized that acute virus infections are
associated with intense activation of the immune system.
Dramatic expansion of T cells — largely those of the CD8+
subset — has been observed both during natural human
infections and in experimental animal models of infection.
A paradox has surrounded this observation, however,
namely that, until recently, the total number of activated
CD8+ T cells appeared to greatly exceed the number of
CD8+ T cells that specifically recognized viral antigens.
The implication was that the vast majority of cells prolifer-
ating during infection were activated in a ‘bystander’
manner that was not specific for the viral antigen. 
This bystander method of activation is exemplified by the
antiviral immune response that occurs following infection
of mice with lymphocytic choriomeningitis virus (LCMV).
In this experimental model, CD8+ T cell numbers increase
rapidly after infection and reach levels at the peak of the
response (8 days after infection) that are 5–10-fold higher
than those before infection; the majority (50–80%) of these
CD8+ T cells show evidence of being activated, as judged
by labelling with DNA precursors to measure proliferation
or by expression of cell-surface activation markers or intra-
cellular effector molecules [1–3]. Despite this massive pro-
liferation, it appeared that only a small proportion of the
expanded cells were specific for the antigen. Estimates of
the frequency of anti-LCMV CD8+ T cell precursors
varied but, despite reports of frequencies of up to 10%
LCMV-specific cells in the spleen [4], the commonly
accepted frequency for LCMV-specific cells at the peak of
the response was 1–5% of CD8+ T cells. Three groups
working in the LCMV system, however, have now shown
that the actual number of antigen-specific CD8+ T cells is
much higher than previously calculated [5–7]. In these
studies, 24–70% of the CD8+ T cells were shown to be
specific for LCMV epitopes, indicating that a much smaller
proportion of the cells were activated in a bystander way.
Why is there such a discrepancy with previous estimates?
The answer lies in the different approaches taken to enu-
merate LCMV-specific cells.
Although methods have long been available for the isola-
tion of antigen-specific B cells and antibodies, identifica-
tion of antigen-specific T cells has been much more
troublesome. This difficulty stems from the nature of
antigen recognition by the T cell. As the T-cell receptor
(TCR) does not recognize native antigen, but rather short
peptide fragments bound to molecules of the major histo-
compatibility complex (MHC), it is technically difficult to
produce ligands for detecting cells that express TCRs
with a particular antigen specificity. More importantly,
interactions between individual TCRs and peptide–MHC
complexes are of such low affinity that extremely sensitive
techniques are required to detect their occurrence. For
this reason, antigen-specific T cells have historically been
detected indirectly using functional readouts of their
activity; for CD8+ T cells, this has generally involved mea-
suring the cytolytic activity of cell populations either
taken directly ex vivo, or after a brief period of reactivation
against antigen-presenting cells in vitro.
Although this assay is adequate for determining relative
differences in specific cell number and activity, its useful-
ness for enumerating antigen-specific cells is much more
questionable. For enumeration, the procedure is performed
as limiting dilution analysis (LDA), which involves aliquot-
ing titrated numbers of cells from the population in ques-
tion into individual assay wells of cell culture plates. These
cells are then expanded in the presence of antigen,
antigen-presenting cells and interleukin-2 (IL-2) for
1–2 weeks. At the end of this stimulation, the frequency of
cytolytic precursors is calculated from the percentage of
wells with detectable lytic activity and the number of cells
seeded per well. The success of LDA in detecting antigen-
specific cells depends on the ability of the original seeded
cells to expand, survive and express lytic activity after
2 weeks in culture (Box 1a). As the fulfilment of these cri-
teria will depend on the state of activation and responsive-
ness of the precursor, this procedure may considerably
underestimate the actual frequency of precursor cells. Nev-
ertheless, this is the method that has generally been used
to estimate the frequency of antigen-specific cells during
anti-viral immune responses, yielding the low estimates for
LCMV-specific CD8+ T-cell frequency detailed above.
Three recent papers highlight the use of new approaches
for quantifying antigen-specific CD8+ T cells [5–7].
These include both indirect and direct methods for the
detection of T-cell interaction with antigen. The indirect
procedure, like LDA, involves measuring an effector func-
tion of CD8+ T cells, in this case the production of inter-
feron-γ (IFN-γ). However, the notable advantage of this
procedure over LDA is that IFN-γ production can be
detected at the single-cell level and hence there is no
requirement for antigen-specific cells to expand in order
to be scored positive in these assays. In addition, because
the cells do not need to expand, the cells need to survive
for only a relatively brief period in culture (5–36 hours).
Two techniques were used for the detection of IFN-γ-pro-
ducing cells (Box 1b). In the enzyme-linked immunospot
(ELISPOT) assay, cell suspensions are placed in culture
wells that have been coated in anti-IFN-γ antibody and
are cultured in the presence of antigen; IFN-γ that is
secreted in response to stimulation is captured by the anti-
body surrounding the cell [8]. After subsequent color
development steps, a discrete colored spot is formed in
the well for each cytokine-secreting cell that has been
plated. In the second method, involving intracellular
staining, cells are briefly stimulated with antigen and then
permeabilized and stained with a fluorochrome-labelled
monoclonal antibody specific for IFN-γ. Positively stain-
ing cells are scored by flow cytometry, a technique which
detects fluorescently labelled cells within a population.
For direct detection of antigen-specific CD8+ T cells, a
newly identified technique known as ‘tetramer’ staining
has been used to overcome the major difficulties in assess-
ing TCR–antigen interaction described earlier [9]. Here,
soluble peptide–MHC ligands for TCRs are produced in
tetrameric rather than in monomeric form. This multiva-
lent antigen is able to interact with antigen-specific T
cells with sufficient avidity to allow for direct measure-
ment of binding. Thus, fluorochrome-labelled tetramers
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Box 1
Quantitation of antigen-specific T cells.
Quantitation of antigen-specific CD8+
T cells. A variety of assays are available for
enumerating CD8+ T cells reactive to
specific antigens (these cells are
represented as red cells with cells reactive
to unrelated antigens shown in blue).
(a) Limiting dilution analysis. Serial dilutions
of the starting cell population are aliquoted
into 96-well cell culture plates. The cells are
stimulated with antigen-presenting cells
(APCs) in the presence of IL-2 for
1–2 weeks in order to expand precursor
cells. At the end of the stimulation, individual
wells are assayed for cytolytic activity
against antigen-pulsed, 51Cr-labelled
targets. The dilution that corresponds to one
precursor cell per well is calculated based
on the Poisson distribution of negative wells
[14]. As highly activated cells are prone to
undergo apoptosis upon restimulation with
antigen in vitro, they may not score as
positive in this assay [15]. Similarly, cells
that do not proliferate sufficiently or that fail
to express cytolytic activity at the end of the
stimulation period will not be detected.
(b) Cytokine production. (i) Detection by
ELISPOT assay [8]. Dilutions of the cell
population are plated into wells coated with
anti-IFN-γ antibodies and are stimulated with
antigen for 18–36 h. After stimulation, cells
are washed away and any IFN-γ secreted by
the cells and captured by anti-IFN-γ
antibodies is detected by sequential
incubation with a second, biotinylated anti-
IFN-γ antibody (specific for a determinant
distinct from that of the first antibody),
enzyme-coupled streptavidin and
appropriate colorimetric substrate. The result
is a discrete colored spot (green) for each
cytokine-secreting cell that was originally
plated. (ii) Detection by intracellular staining.
Cells are briefly (5 h) stimulated with antigen
in the presence of an inhibitor of intracellular
protein transport (usually brefeldin A). The
purpose of the inhibitor is to block secretion
of the cytokine and promote its intracellular
accumulation. Subsequently, the cells are
permeabilized and treated with
fluorochrome-labelled anti-IFN-γ antibody.
Positive cells (green) are scored by flow
cytometry. In both of these cytokine
detection assays, the cells need to undergo
activation and express an effector function,
although there is no requirement for
proliferation or long-term survival. 
(c) Tetramer staining [9]. Fluorescently
labelled tetrameric complexes of
peptide–MHC class I complexes are
constructed by attaching biotinylated,
peptide-loaded MHC monomers to
fluorochrome-labelled streptavidin (which
has four binding sites for biotin). This reagent
is added directly to cell suspensions, and
binds specifically to the TCR of the
appropriate antigen-specific cells. Cells that
stain positive are detected by flow cytometry.
There is no requirement for T-cell activation
or effector function in this assay.
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of peptide–MHC class I complexes are added to cell sus-
pensions and antigen-specific cells are simply scored by
flow cytometry (Box 1c). This procedure has the great
advantage of staining antigen-specific T cells indepen-
dently of their ability to survive, expand or express effec-
tor function in vitro. The disadvantages are that the
particular antigenic epitope must be known, and that the
detection reagents — the tetramers — must be custom-
made for each individual antigenic specificity.
Each of these new techniques was used to reassess the fre-
quency of LCMV-specific CD8+ T cells that is generated
following LCMV infection of mice. Reassuringly, each
approach independently gave a very similar value, ranging
from 24% to 70% of the total number of CD8+ T cells. It
was shown directly that the different techniques were
detecting the same population of cells by an experiment
in which tetramer-stained cells were sorted and assayed by
ELISPOT; virtually every sorted cell also stained positive
in the ELISPOT assay [5]. Furthermore, by direct com-
parison it was shown that the frequency of specific cells
detected by ELISPOT was 20–100-fold higher than that
measured by LDA 8 days after infection. Thus, only a
small proportion of the activated antigen-specific T cells
were able to meet the requirements to score positive by
LDA. Presumably, the remaining cells either undergo
apoptosis or fail to proliferate sufficiently, which might be
expected given that these cells have recently been acti-
vated in vivo. More surprising, however, is the observation
that LDA still underestimated LCMV-specific frequen-
cies by 10–20-fold 120 days after infection. Clearly, LDA
detects antigen-specific cells very inefficiently.
The conclusion from these studies is that the majority of
CD8+ T cells that are activated following LCMV infec-
tion are in fact virus-specific. Further studies in which the
new technologies are applied to other virus infections will
be useful in establishing the generality of this phenome-
non, but given that most of the previous estimates of
antigen-specific frequency were derived from LDA, it is
likely that similar answers will be found. Consistent with
this, a high proportion of CD8+ T cells activated after
infection of mice with herpes simplex virus were shown to
express a restricted TCR — that is, a TCR specific for a
virally encoded antigen — implying that much of the
expansion in this infection was antigen-specific [10]. Does
this mean that all of the T cells responding after virus
infection are antigen-specific, or does some bystander
activation also occur? 
Here, a careful examination of the available data is
required. Given the historical difficulties in identifying
antigen-specific T cells, there is little direct data on
bystander activation. However, it has been shown that
CD8+ T cells proliferate in a TCR-independent manner in
vivo after induction of the type I interferons, IFN-α and
IFN-β, which is characteristic of an anti-viral response,
suggesting that this TCR-independent proliferation will
occur following virus infection [3]. It is important to note
that this proliferation was restricted to those CD8+ T cells
that had previously been exposed to antigen, that is,
memory CD8+ T cells. The failure of naïve CD8+ T cells
— those that have not yet been exposed to antigen — to
become activated non-specifically by virus infection was
confirmed using T cells from transgenic mice generated to
express TCRs with a single antigen specificity [6,11,12].
Whether or not memory CD8+ T cells undergo bystander
activation after virus infection is less clear. In the present
work, no increase in the number of LCMV-specific CD8+
T cells was observed 7 days after infecting LCMV-immu-
nized mice with the unrelated vaccinia virus, implying
that the memory cells generated against the first virus did
not proliferate [5]. These cells, however, did exhibit
increased ex vivo cytolytic activity against LCMV-infected
target cells, indicating that they had in fact been activated
in a bystander way. This is consistent with previous
reports of reactivation of lytic activity of antigen-specific
CD8+ T cells by infection with non-related viruses [13].
Why increased numbers of memory cells were not
observed after the second virus infection is unclear, but it
is possible that the assay may not be sensitive enough to
detect small increases in the cell number that may occur if
bystander proliferation involves only a limited number of
divisions. Direct assessment of this issue awaits the use of
DNA precursors in combination with staining of antigen-
specific memory cells to monitor cell division in vivo.
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